赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis)):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIIR2016142)
◆英語タイトル:Shigella Infections (Shigellosis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
◆発行会社/調査会社:DelveInsight
◆商品コード:DIIR2016142
◆発行日:2018年12月
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:約100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後3営業日)
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis)):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)]についてメールでお問い合わせはこちら
※当調査レポートでは、赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))治療薬の世界市場動向について調査・分析し、以下の構成でお届けいたします。

・赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis)):適応症(疾患)の概要
・市販医薬品の状況
・世界のAPI(医薬品原薬)メーカー分析
・地域別APIメーカー状況(アメリカ、ヨーロッパ、中国など)
・赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))のフェーズ3治験薬の状況
・赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))治療薬の市場規模(販売予測)
・赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))の市販医薬品分析
 (医薬品名、説明、APIメーカー、承認状況、特許など)
・赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))のフェーズ3治験薬分析
・開発中止中の赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))治療薬剤
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s Report, “Shigella Infections (Shigellosis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Shigella Infections (Shigellosis) Report is to understand the market and pipeline status of the drugs around the Shigella Infections (Shigellosis) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2020. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Shigella Infections (Shigellosis). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


SCOPE:
• A snapshot of the global Market and Phase III therapeutics scenario for Shigella Infections (Shigellosis).
• A review of the marketed products under prescription for Shigella Infections (Shigellosis), regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Shigella Infections (Shigellosis) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Shigella Infections (Shigellosis) drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Shigella Infections (Shigellosis) drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Shigella Infections (Shigellosis) drugs.
• Coverage of Shigella Infections (Shigellosis) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure to 2020.


*** レポート目次(コンテンツ)***

1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2020
6. Marketed Drugs for Shigella Infections (Shigellosis)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Shigella Infections (Shigellosis)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Shigella Infections (Shigellosis)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables
• Shigella Infections (Shigellosis) Therapeutic Market, US, Marketed Drugs by Application Type, 2018
• Shigella Infections (Shigellosis) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2018
• Shigella Infections (Shigellosis) Therapeutic Market, US, (Year), 2018
• Shigella Infections (Shigellosis) Marketed Drugs, API Manufacturers by US DMF Status, 2018
• Shigella Infections (Shigellosis) Marketed Drugs, US DMF Status Drug Specific (Number), 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, Europe by Country, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, India by State, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, China by Province, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers by Geography 2018
• Shigella Infections (Shigellosis) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2018
• Shigella Infections (Shigellosis) Therapeutic Market, Global Sales-2020 (in million USD)
• API Manufacturers for Drug, 2018
• Phase III Drugs for Shigella Infections (Shigellosis), 2018
• Discontinued Drugs for Shigella Infections (Shigellosis), 2018


List of Figures
• Shigella Infections (Shigellosis) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2018
• Shigella Infections (Shigellosis) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2018
• Shigella Infections (Shigellosis) Therapeutic Market, US, (Year), 2018
• Shigella Infections (Shigellosis) Marketed Drugs, API Manufacturers by US DMF Status (%), 2018
• Shigella Infections (Shigellosis) Marketed Drugs, US DMF Status Drug Specific (Number), 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, Europe by Country, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, India by State, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers, China by Province, 2018
• Shigella Infections (Shigellosis) Drugs, API Manufacturers by Geography 2018
• Shigella Infections (Shigellosis) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2018
• Shigella Infections (Shigellosis) Therapeutic Market, Global Sales 2020 (in million USD)
• Drug, Patent/Exclusivity Expiry (Year), 2018


*** レポートのキーワード ***

赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis))、薬剤、治療薬、市場規模、販売量、医薬品有効成分(API)メーカー、治験、上市品(市販薬)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 手工具市場(~2019):日本
    This industry report offers the most up-to-date market data on the actual market situation, trends and future outlook for non-power-driven hand tools in Japan. The research includes historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for indu …
  • Pharmesis International Ltd. (P31):企業の財務、戦略的SWOT分析
    Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • フラットウッドドリルビットの世界市場
    Flat Wood Drill Bit Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Ge …
  • 集合住宅の建設市場(~2018):フィンランド
    This report is the result of Timetric’s extensive market research covering the multi-family housing construction industry in Finland. It contains detailed historic and forecast market value data for the multi-family housing construction industry, including a breakdown of the data by construction act …
  • Anti-CD152 Antibody:抗体のグローバル市場2015(薬開発、治験動向)
    DelveInsight’s,“Anti-CD152 Antibody-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Anti-CD152 Antibody. This report …
  • 世界の被膜ガラス市場2016
    Notes:Production, means the output of Coating Glass Revenue, means the sales value of Coating Glass This report studies Coating Glass in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, productio …
  • 中国の豚繁殖・呼吸障害症候群ワクチン市場動向(2013-2017)
    In China, PRRS is the most serious disease that impairs the pig raising & breeding industry. It inflicted heavy losses on China pig raising & breeding industry for many times. In April 2007, Ministry of Agriculture of China issued Technical Standards of Highly Pathogenic Porcine Reproductive and Res …
  • Mustang Engineering, L.P.(代替エネルギー分野):企業のM&A・提携動向
    Summary Mustang Engineering, L.P. (Mustang) is an engineering management company. It provides engineering, project management, procurement, and construction management services. The company’s service portfolio includes design and engineering, procurement, project systems management, construction man …
  • 世界及び中国のオルメサルタンメドキソミル市場2017
    The 'Global and Chinese Olmesartan Medoxomil Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Olmesartan Medoxomil industry with a focus on the Chinese market. The report provides key statistics on the market status of the Olmesartan …
  • OKP Holdings Limited (5CF):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "OKP Holdings Limited" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. World Market Intellige …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIIR2016142 )"赤痢菌感染症(赤痢)(Shigella Infections (Shigellosis)):治療薬市場2018(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)" (英文:Shigella Infections (Shigellosis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。